Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -156.9%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $104M | $139M | $24M | $74M | — | — | — | — |
| Enterprise Value | $92M | $127M | $22M | $65M | — | — | — | — |
| P/E Ratio → | -0.48 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 4.68 | 11.72 | 8.39 | 5.61 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -156.9% | -156.9% | -202.3% | -80.1% | — | — | -194.0% | -67.9% |
| ROA | -122.9% | -122.9% | -147.4% | -110.6% | -217.5% | -102.8% | -62.2% | -58.1% |
| ROIC | -3381.9% | -3381.9% | -475.7% | — | — | — | — | — |
| ROCE | -159.8% | -159.8% | -202.7% | -201.1% | — | -155.6% | -74.6% | -72.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.05 | 0.01 | — | — | — | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -0.84 | -0.64 | — | — | — | -0.46 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -33.55 | -91.71 | -469.87 | — | — |
Net cash position: cash ($12M) exceeds total debt ($110000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.92 | 5.92 | 1.92 | 3.91 | 0.21 | 1.27 | 7.04 | 7.67 |
| Quick Ratio | 5.92 | 5.92 | 1.92 | 3.91 | 0.21 | 1.27 | 7.04 | 7.67 |
| Cash Ratio | 5.55 | 5.55 | 1.48 | 3.73 | 0.19 | 1.22 | 6.92 | 7.44 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $14M | $556279 | $344653 | $136404 | $136404 | $136381 | $136120 |
Clinical-stage liquidity constraints
According to recent market data, INTS trades at a price-to-book ratio of 4.68, which suggests that investors are pricing the firm based on its intellectual property potential rather than its current book value, as reported in financial statements and corroborated by peer valuation trends in the biotech sector.
The lack of meaningful P/E or EV/EBITDA multiples underscores the company's pre-revenue status, where traditional valuation metrics fail to capture the speculative value of the DfuseIT platform. Investors should monitor whether this premium valuation can be sustained as the company approaches critical data readouts, or if the market will demand a higher margin of safety given the current cash burn.
Based on reported figures, the company's ROIC has remained consistently negative, reaching a low of -2545.5% in 2025Q1, which highlights the extreme difficulty of generating returns on invested capital while the firm is entirely focused on high-cost, non-revenue-generating clinical development activities for its lead oncology candidate.
The volatility in ROIC reflects the lumpy nature of R&D spending and the absence of any commercial product to offset the capital base. This trend suggests that the company is currently in a value-destructive phase, which is typical for early-stage biotech but warrants investigation into whether future milestones can realistically pivot the firm toward positive capital compounding.
As reported in financial statements, the current ratio has fluctuated wildly from 0.63 to 5.92 over the last ten quarters, indicating that the company's ability to meet short-term obligations is highly sensitive to the timing of equity raises and the pace of clinical trial site expenditures.
The extreme variance in liquidity ratios suggests that management operates with a very thin margin of safety, leaving the firm vulnerable to any unexpected delays in clinical enrollment or regulatory hurdles. Investors should monitor the current ratio closely, as a return to the sub-1.0 levels observed in 2025Q1 would likely signal an immediate need for dilutive financing.
As indicated by the provided data, the market's reliance on traditional P/E ratios for INTS is fundamentally flawed, as the company lacks commercial revenue and is currently in a phase where earnings are intentionally suppressed by heavy R&D investment to validate its proprietary DfuseIT delivery platform.
Using P/E to evaluate this business model obscures the true value driver, which is the clinical progress of the INT230-6 program rather than current profitability. Analysts should instead focus on cash runway duration and the probability of success in clinical trials, as these metrics provide a more accurate assessment of the firm's long-term viability than any earnings-based multiple.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INTS stock.
Intensity Therapeutics, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Intensity Therapeutics, Inc.'s return on equity (ROE) is -156.9%. The historical average is -140.2%.
Based on historical data, Intensity Therapeutics, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.